Polyethylene glycol
Accession Number
Small Molecule
Approved, Vet approved

Polyethylene glycol (PEG) is a synthetic polymer produced via polymerization of ethylene oxide molecules to make joining units of ethylene glycol by an ether linkage.2,3 PEGs are water-soluble polymers that can form hydrogen bonds in a ratio of 100 water molecules per one PEG molecule.2 Molecular weights of PEGs vary by time of the polymerization process and the molecular weight represents the weighted average of the individual PEG molecules. PEGs differ in their physical and chemical properties depending on their molecular weight: PEGs are liquids when molecular weights are <1000 and the molecule turns to waxy solids with increasing molecular weights.3 The most common preparations of PEGs include PEG 3350 and PEG 400. PEGs have various applications in many fields, ranging from medical to industrial areas. PEGs have a long history of gastroenterology: PEG 3350 is a common over-the-counter osmotic laxative used to relieve occasional constipation.8 PEG 3350 is also used for cleansing of the colon in preparation for colonoscopy in adults.5

The rationale of using PEG in gastroenterology is due to the physical properties of the compound: its potent water-binding capacity, negligible intestinal absorption with increasing molecular mass, lack of significant toxicity, and limited intestinal enzymatic degradation or bacterial metabolism all make PEG a useful therapeutic agent for the treatment of occasional constipation and bowel cleansing for preparation in colonoscopy.1

  • Macrogol
  • Macrogol 3350
  • Macrogol 4000
  • Macrogol 6000
  • PEG
  • Polyethylene glycol 3350
  • Polyethylene glycol 4000
  • Polyethylene glycol 6000
Product Ingredients
IngredientUNIICASInChI Key
Polyoxyethylene 23 lauryl etherN72LMW566GNot AvailableNot applicable
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
GialaxKit1 g/1gOralPhlight Pharma, Llc2011-10-01Not applicableUs
Polyethylene Glycol 3350 NF PEGyLAXPowder, for solution17 g/17gOralMartin Ekwealor Pharmaceuticals, Inc.2013-12-16Not applicableUs
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
GavilaxPowder, for solution17 g/17gOralDirectrx2015-01-01Not applicableUs
Polyethylene Glycol 3350Powder, for solution17 g/17gOralNucare Pharmaceuticals,inc.2006-09-06Not applicableUs
Polyethylene Glycol 3350Powder, for solution17 g/17gOralPaddock Laboratories, LLC2006-05-242020-10-31Us
Polyethylene Glycol 3350Powder, for solution17 g/17gOralAtlantic Biologicals Corps.2006-09-06Not applicableUs
Polyethylene Glycol 3350Powder1 g/1gOralAv Kare, Inc.2013-07-05Not applicableUs
Polyethylene Glycol 3350Powder1 g/1gOralLannett Company, Inc..2011-10-01Not applicableUs
Polyethylene Glycol 3350Powder1 g/1gOralPhysicians Total Care, Inc.2004-10-07Not applicableUs
Polyethylene Glycol 3350Powder, for solution17 g/1OralProficient Rx LP2006-05-24Not applicableUs
Polyethylene Glycol 3350Powder, for solution17 g/1OralNexgen Pharma, Inc.2006-09-27Not applicableUs
Polyethylene Glycol 3350Powder, for solution17 g/17gOralGolden State Medical Supply2013-02-082018-10-11Us
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Basic Care ClearlaxPowder, for solution17 g/17gOralL. Perrigo Company2017-08-10Not applicableUs
Berkley and Jensen ClearlaxPowder, for solution17 g/17gOralBJWC2009-12-17Not applicableUs
BET-R-PrepPowder, for solution17 g/17gOralSatius Pharmaceuticals, Llc2017-11-27Not applicableUs
Care One ClearlaxPowder, for solution17 g/17gOralAmerican Sales Company2009-10-09Not applicableUs
ClarilaxPowder, for solutionOralPharmascience IncNot applicableNot applicableCanada
Clear LaxPowder, for solution17 g/17gOralMeijer Distribution Inc2009-10-06Not applicableUs
Clear LaxPowder, for solution17 g/17gOralMeijer Distribution2009-10-062013-10-19Us
Clear LaxPowder, for solution17 g/17gOralH E B2009-10-08Not applicableUs
Clear LaxPowder, for solution17 g/17gOralMeijer Distribution Inc2017-07-12Not applicableUs
Clear Lax Original Prescription StrengthPowder, for solution17 g/17gOralHYVEE INC2009-10-112020-03-23Us
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Aquasite DpsPolyethylene glycol (.2 %) + Dextran 70 (.1 %)Solution / dropsOphthalmicCiba Vision1993-12-312000-11-08Canada
Bi-peglytePolyethylene glycol (59.55 g) + Bisacodyl (5 mg) + Potassium chloride (0.76 g) + Sodium bicarbonate (1.69 g) + Sodium chloride (1.46 g) + Sodium sulfate (5.74 g)Kit; Powder, for solution; Tablet, delayed releaseOralPendopharm Division Of Pharmascience Inc2010-06-06Not applicableCanada
Clenz-LytePolyethylene glycol (236 g/4L) + Potassium chloride (2.97 g/4L) + Sodium bicarbonate (6.74 g/4L) + Sodium chloride (5.86 g/4L) + Sodium sulfate (22.74 g/4L)Powder, for solutionNasogastric; OralPaddock Laboratories, Inc.2010-06-072010-06-07Us
ColytePolyethylene glycol (857.69 mg) + Potassium chloride (10.65 mg) + Sodium bicarbonate (24.02 mg) + Sodium chloride (20.87 mg) + Sodium sulfate (81.2 mg)Powder, for solutionNasogastric; OralPendopharm Division Of Pharmascience Inc1986-12-31Not applicableCanada
ColytePolyethylene glycol (227.1 g/3.785L) + Potassium chloride (2.82 g/3.785L) + Sodium bicarbonate (6.36 g/3.785L) + Sodium chloride (5.53 g/3.785L) + Sodium sulfate decahydrate (21.5 g/3.785L)Powder, for solutionNasogastric; OralAlaven Pharmaceutical2010-09-012016-05-31Us
ColytePolyethylene glycol (240 g/4L) + Potassium chloride (2.98 g/4L) + Sodium bicarbonate (6.72 g/4L) + Sodium chloride (5.84 g/4L) + Sodium sulfate decahydrate (22.72 g/4L)Powder, for solutionNasogastricMEDA Pharmaceuticals2014-08-052021-09-30Us
Colyte with flavor packsPolyethylene glycol (240 g/4L) + Potassium chloride (2.98 g/4L) + Sodium bicarbonate (6.72 g/4L) + Sodium chloride (5.84 g/4L) + Sodium sulfate decahydrate (22.72 g/4L)Powder, for solutionNasogastric; OralAlaven Pharmaceutical1999-04-072016-08-31Us
Electropeg SolutionPolyethylene glycol (238.8 g) + Potassium chloride (3 g) + Sodium bicarbonate (6.7 g) + Sodium chloride (5.8 g) + Sodium sulfate (22.7 g)PowderOralTechnilab Pharma Inc.1998-04-201999-09-27Canada
GaviLyte - C TMPolyethylene glycol (240 g/278.26g) + Potassium chloride (2.98 g/278.26g) + Sodium bicarbonate (6.72 g/278.26g) + Sodium chloride (5.84 g/278.26g) + Sodium sulfate (22.72 g/278.26g)Powder, for solutionOralLupin Pharmaceuticals2009-01-06Not applicableUs
GaviLyte - NPolyethylene glycol (420 g/438.4g) + Potassium chloride (1.48 g/438.4g) + Sodium bicarbonate (5.72 g/438.4g) + Sodium chloride (11.2 g/438.4g)Powder, for solutionOralLupin Pharmaceuticals2009-05-28Not applicableUs
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
GialaxPolyethylene glycol (1 g/1g)KitOralPhlight Pharma, Llc2011-10-01Not applicableUs
PCP 100 KitPolyethylene glycol (17 g/17g) + Bisacodyl (5 mg/1) + Magnesium citrate (1.745 g/29.6mL) + Metoclopramide hydrochloride (10 mg/1) + Petrolatum (0.76 g/1g)KitOralAsclemed Usa, Inc.2014-01-02Not applicableUs
PegPolyethylene glycol (55 g/100g) + Polyethylene glycol 400 (45 g/100g)CreamTopicalBiocellerex, Inc.2015-07-142016-01-05Us
Polyethylene Glycol 3350 NF PEGyLAXPolyethylene glycol (17 g/17g)Powder, for solutionOralMartin Ekwealor Pharmaceuticals, Inc.2013-12-16Not applicableUs
International/Other Brands
Fortrans / GlycoLax / TriLyte
CAS number



Polyethylene glycol is indicated for use as an over-the-counter osmotic laxative to relieve occasional constipation.8 When used in combination with sodium ascorbate, sodium sulfate, ascorbic acid, sodium chloride and potassium chloride, it is used for cleansing of the colon in preparation for colonoscopy in adults.5

Associated Conditions
Associated Therapies

The osmotic effect of PEG produces a copious watery diarrhea. The onset of action of PEG 3350 is about 1 to 2 hours after oral ingestion.5 The colonic transit of polyethylene glycol occurs in a dose-dependent manner.2 When used for bowel preparation before colonscopy, electrolytes are typically added in the oral solution to prevent dehydration and electrolyte disturbances. As an over-the-counter laxative, the OTC product does not contain any salts that can be absorbed.4 In a study involving healthy subjects, PEG 3350 had negligible effects on colonic fluid absorption or with the ability of the colonic mucosa to generate and sustain steep electrochemical gradients.3

Mechanism of action

Osmotic laxatives contain substances that are poorly absorbable and draw water into the lumen of the bowel.9 Polyethylene glycol functions is an osmotic laxative that causes increased water retention in the lumen of the colon by binding to water molecules, thereby producing loose stools.4,5

Additional Data Available
Adverse Effects

Comprehensive structured data on known drug adverse effects with statistical prevalence. MedDRA and ICD10 ids are provided for adverse effect conditions and symptoms.

Learn more
Additional Data Available

Structured data covering drug contraindications. Each contraindication describes a scenario in which the drug is not to be used. Includes restrictions on co-administration, contraindicated populations, and more.

Learn more
Additional Data Available
Blackbox Warnings

Structured data representing warnings from the black box section of drug labels. These warnings cover important and dangerous risks, contraindications, or adverse effects.

Learn more

Following a two-day split-dosing regimen of an oral suspension containing 140 grams of PEG 3350 in healthy subjects, the mean Cmax was 2.7 mcg/mL and the mean Tmax was 3 hours.5 Typically, polyethylene glycols with a high molecular weight are poorly absorbed from the gastrointestinal tract following oral administration.2,3

Volume of distribution

Following a two-day split-dosing regimen of an oral suspension containing 140 grams of PEG 3350 in healthy subjects, the mean volume of distribution was 48,481 L.5

Protein binding

There is limited information on the protein binding profile of polyethylene glycols.


Polyethylene glycol is a metabolically inert laxative that does not undergo intestinal enzymatic degradation or bacterial metabolism.1,4

Route of elimination

Following administration of an oral suspension containing 140 grams of PEG 3350 in healthy subjects, up to 85% to 99% of the compound was excreted in the feces.5

Half life

Following a two-day split-dosing regimen of an oral suspension containing 140 grams of PEG 3350 in healthy subjects, the mean half life was 4.1 hours.5


There is limited information on the clearance rate of polyethylene glycols.


The oral LD50 of PEG 3350 in rats is 22000 mg/kg.10

There is limited clinical information on the overdose of polyethylene glycols. Based on the pharmacological action of the compound, severe diarrhea may be suspected. Overdose of polyethylene glycols should be responded with symptomatic and supportive care.

Affected organisms
  • Humans and other mammals
Not Available
Pharmacogenomic Effects/ADRs
Not Available


Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Abicipar PegolThe therapeutic efficacy of Abicipar Pegol can be decreased when used in combination with Polyethylene glycol.
AcetazolamideThe risk or severity of adverse effects can be increased when Acetazolamide is combined with Polyethylene glycol.
AcetyldigoxinThe serum concentration of Acetyldigoxin can be decreased when it is combined with Polyethylene glycol.
AclidiniumThe therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Aclidinium.
AgmatineThe therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Agmatine.
AlcuroniumThe therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Alcuronium.
AlfentanilThe therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Alfentanil.
AlloinThe risk or severity of adverse effects can be increased when Polyethylene glycol is combined with Alloin.
AlmasilateThe therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Almasilate.
AloglutamolThe therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Aloglutamol.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
  • Avoid alcohol. Withdrawing from alcohol increases the risk of seizures, which is also caused by the drug.
  • Avoid milk and dairy products.
  • Avoid solid foods. Consume only clear liquids from the start of drug treatment until after the colonoscopy.


General References
  1. Hammer HF, Hammer J, Gasche C: [Polyethylene glycol (Macrogol)--an overview of its use in diagnosis and therapy of gastrointestinal diseases]. Wien Klin Wochenschr. 2000 Jan 28;112(2):53-60. [PubMed:10703152]
  2. Minguez M, Lopez Higueras A, Judez J: Use of polyethylene glycol in functional constipation and fecal impaction. Rev Esp Enferm Dig. 2016 Dec;108(12):790-806. doi: 10.17235/reed.2016.4571/2016. [PubMed:27871178]
  3. Fordtran JS, Hofmann AF: Seventy Years of Polyethylene Glycols in Gastroenterology: The Journey of PEG 4000 and 3350 From Nonabsorbable Marker to Colonoscopy Preparation to Osmotic Laxative. Gastroenterology. 2017 Mar;152(4):675-680. doi: 10.1053/j.gastro.2017.01.027. Epub 2017 Jan 29. [PubMed:28147222]
  4. Portalatin M, Winstead N: Medical management of constipation. Clin Colon Rectal Surg. 2012 Mar;25(1):12-9. doi: 10.1055/s-0032-1301754. [PubMed:23449608]
  5. PLENVU (polyethylene glycol 3350, sodium sulfate, ascorbic acid, sodium chloride and potassium chloride for oral solution) US FDA 2018 Label [Link]
  6. PegaLAX (polyethylene glycol 3350) 2017 Canadian Prescribing Information [Link]
  7. NCBI StatPearls [Internet]: Bowel Preparation [Link]
  8. DailyMed Label: GAVILAX (Polyethylene glycol 3350) powder, for solution [Link]
  9. Laxatives - StatPearls - NCBI Bookshelf [Link]
  10. Spectrum Chemical: POLYETHYLENE GLYCOL 3350 Safety Data Sheet [Link]
External Links
PubChem Substance
ATC Codes
A06AD15 — MacrogolA06AD65 — Macrogol, combinations
AHFS Codes
  • 56:12.00 — Cathartics and Laxatives
FDA label
Download (539 KB)
Download (710 KB)

Clinical Trials

Clinical Trials
0Not Yet RecruitingOtherMetastatic Sarcoma / Recurrent Sarcoma / Resectable Sarcoma1
0RecruitingSupportive CareDiverticulitis / Inflammatory Bowel Diseases (IBD) / Neoplasms, Colorectal / Surgical Site Infections1
1CompletedDiagnosticGastrointestinal Hemorrhage1
1CompletedTreatmentChronic Constipation1
1CompletedTreatmentColorectal Cancers1
1CompletedTreatmentGastric Emptying / Healthy Volunteers1
1Not Yet RecruitingTreatmentPharmacokinetics1
1, 2CompletedTreatmentAutism Spectrum Conditions/Disorders / Gastrointestinal Problems1
1, 2Not Yet RecruitingScreeningBowel Preparation for Pediatric Colonoscopy / Bowel preparation therapy1
1, 2Not Yet RecruitingTreatmentNerve Injury / Peripheral Nerve Injury (PNI)1
1, 2RecruitingTreatmentCrohn's Disease (CD)1
1, 2Unknown StatusTreatmentAnti-Biotic Resistance / Klebsiella Pneumoniae1
2Active Not RecruitingTreatmentBowel Preparation Before Colonoscopy1
2CompletedDiagnosticMalignant Neoplasm of Colon1
2CompletedOtherBowel preparation therapy1
2CompletedOtherColon Prep for Colonoscopy1
2CompletedScreeningHealthy Volunteers1
2CompletedTreatmentCrohn's Disease (CD)1
2CompletedTreatmentMalignant Neoplasm of Colon1
2RecruitingTreatmentAutism Spectrum Conditions/Disorders / Constipation / Diarrhea / Gastro-Intestinal Disorder1
2RecruitingTreatmentAutism Spectrum Conditions/Disorders / Gastrointestinal Disorder1
2RecruitingTreatmentCrohn's Disease (CD)1
2, 3RecruitingTreatmentClostridium Difficile1
3CompletedNot AvailableBowel Preparation for Colonoscopy1
3CompletedNot AvailableColonoscopy1
3CompletedDiagnosticBowel Preparation for Colonoscopy1
3CompletedDiagnosticBowel Preparation, Efficacy, Tolerability, Safety1
3CompletedDiagnosticPatients Who Receive Colonoscopy1
3CompletedOtherBowel Cleansing Efficacy / Unrecognized Condition1
3CompletedScreeningCarcinoma, Colorectal / Colon Cleansing / Colorectal Cancers1
3CompletedSupportive CareColon Adenomas / Colorectal Cancers1
3CompletedSupportive CareColonic Diseases / Diabetes Mellitus1
3CompletedTreatmentBowel Preparation Prior to Endoscopic, Radiological and Other Examinations as Well as to Surgical Procedures Which Require Empty Bowel1
3CompletedTreatmentBowel preparation therapy / Colonoscopy / Endoscopy1
3CompletedTreatmentColon Cleansing1
3CompletedTreatmentColon Diseases / Colonoscopy Preparation1
3CompletedTreatmentHealthy Volunteers1
3CompletedTreatmentMalignant Neoplasm of Colon1
3Not Yet RecruitingTreatmentConstipation - Functional1
3Not Yet RecruitingTreatmentConstipation / Illness, Critical1
3Not Yet RecruitingTreatmentFunctional Constipation1
3RecruitingOtherDigestive System Diseases1
3RecruitingTreatmentBowel Preparation Before Colonoscopy1
3Unknown StatusDiagnosticColonoscopy1
4Active Not RecruitingDiagnosticColon Adenomas / Colon Lesion / Colon Polyps1
4Active Not RecruitingOtherColorectal Polyps1
4CompletedNot AvailableColonoscopy1
4CompletedBasic ScienceFunctional Constipation / Irritable Bowel Syndrome Characterized by Constipation1
4CompletedDiagnosticColonoscopy Preparation1
4CompletedOtherChronic Constipation1
4CompletedOtherCleansing Quality of the Colon1
4CompletedOtherSmall Bowel Diseases1
4CompletedScreeningAdenoma Detection Rate / Bowel Preparation Scale1
4CompletedScreeningColorectal Cancers1
4CompletedTreatmentBowel Preparation for Colonoscopy1
4CompletedTreatmentChronic Constipation1
4CompletedTreatmentColon Cleansing1
4CompletedTreatmentColon Cleansing for Colonoscopy1
4CompletedTreatmentColonoscopy Preparation1
4CompletedTreatmentColorectal Cleansing Prior Operation1
4CompletedTreatmentGastrointestinal Diseases1
4CompletedTreatmentIntestinal Cancer1
4CompletedTreatmentMalignant Neoplasm of Colon1
4CompletedTreatmentOpioid Induced Constipation (OIC)1
4CompletedTreatmentPreparation for Colonoscopy1
4CompletedTreatmentSubjets Requiring a Colonoscopy1
4Enrolling by InvitationDiagnosticColonoscopy1
4Not Yet RecruitingSupportive CareColorectal Cancers1
4RecruitingDiagnosticBowel Preparation Solutions1
4RecruitingDiagnosticBowel preparation therapy1
4RecruitingDiagnosticPolyethylene Glycol / Sodium Phosphate1
4RecruitingDiagnosticUlcerative Colitis1
4RecruitingHealth Services ResearchColorectal Cancers1
4RecruitingOtherCapsule Endoscopy / Gluten Enteropathy / Inflammatory Bowel Diseases (IBD)1
4RecruitingPreventionPostoperative Bowel Movement / Postoperative Passage of Flatus1
4RecruitingTreatmentAcute on Chronic Liver Failure / Acute-On-Chronic Liver Failure / Hepatic Encephalopathy (HE)1
4RecruitingTreatmentChronic Functional Constipation / Functional Constipation1
4RecruitingTreatmentConstipation / Peritoneal dialysis complication1
4RecruitingTreatmentCystic Fibrosis Gastrointestinal Disease1
4RecruitingTreatmentFissure in Ano1
4RecruitingTreatmentHepatic Encephalopathy (HE)1
4TerminatedNot AvailableBowel preparation therapy1
4TerminatedNot AvailableColonoscopy Preparation1
4TerminatedDiagnosticColonoscopy Failure / Poor Bowel Preparation1
4TerminatedSupportive CareConstipation / Malignancies1
4Unknown StatusNot AvailableClostridium Difficile Colitis1
4Unknown StatusNot AvailableMalignant Neoplasm of Colon / Rectal Carcinoma1
4Unknown StatusHealth Services ResearchColonoscopy1
4Unknown StatusTreatmentConstipation1
4WithdrawnTreatmentDiurnal Enuresis1
4WithdrawnTreatmentNocturnal Enuresis1
Not AvailableCompletedNot AvailableColonoscopy Preparation2
Not AvailableCompletedNot AvailableEase of Bowel Preparation and Patient Tolerability / Efficacy of Bowel Preparation1
Not AvailableCompletedNot AvailableEffectiveness of SMS to Fix PC Interval1
Not AvailableCompletedNot AvailableHyponatremia1
Not AvailableCompletedNot AvailableSpinal Cord Injuries (SCI)1
Not AvailableCompletedNot AvailableThe Timing of Bowel Preparation in Outpatient Colonoscopy1
Not AvailableCompletedDiagnosticBowel preparation therapy1
Not AvailableCompletedDiagnosticColonoscopy1
Not AvailableCompletedDiagnosticDiabetes Mellitus1
Not AvailableCompletedHealth Services ResearchAcute Kidney Injury (AKI)1
Not AvailableCompletedOtherBowel preparation therapy1
Not AvailableCompletedPreventionFunctional Disorder of Intestine1
Not AvailableCompletedPreventionHemolytic-uremic Syndrome (HUS) / Hemorrhagic Colitis / Intestinal Infection Due to E. Coli / Intestinal Infectious Disease1
Not AvailableCompletedPreventionPost Procedural Constipation1
Not AvailableCompletedScreeningUlcerative Colitis1
Not AvailableCompletedTreatmentConstipation1
Not AvailableCompletedTreatmentHepatic Encephalopathy (HE) / Liver Cirrhosis / Portosystemic Encephalopathy / PSE1
Not AvailableCompletedTreatmentInflammatory Bowel Diseases (IBD)1
Not AvailableCompletedTreatmentUrge Syndrome1
Not AvailableRecruitingNot AvailableDigestive Illness1
Not AvailableRecruitingBasic ScienceMicrobiota1
Not AvailableRecruitingDiagnosticCTE1
Not AvailableRecruitingDiagnosticColonoscopy1
Not AvailableRecruitingDiagnosticColorectal Disorders1
Not AvailableRecruitingPreventionRectal Carcinoma1
Not AvailableRecruitingScreeningColonoscopy1
Not AvailableTerminatedTreatmentColonoscopy1
Not AvailableTerminatedTreatmentConstipation1
Not AvailableTerminatedTreatmentFecal Incontinence1
Not AvailableUnknown StatusDiagnosticBowel Preparation for Colonoscopy1
Not AvailableUnknown StatusDiagnosticBowel preparation therapy1
Not AvailableUnknown StatusDiagnosticColonic Adenomas1
Not AvailableWithdrawnScreeningPatients Undergoing Screening or Surveillance Colonoscopy1
Not AvailableWithdrawnTreatmentAltered Mental Status / AMS / HE / Hepatic Encephalopathy (HE) / Liver Cirrhosis1
Not AvailableWithdrawnTreatmentColonoscopy1


Not Available
Not Available
Dosage forms
Solution / dropsOphthalmic
Kit; powder, for solution; tablet, delayed releaseOral
Powder, for solutionOral100 %
Powder, for solutionTopical17 g/1
Powder, for solutionNasogastric
PowderTopical17 g/17g
PowderOral17 g/17g
KitOral1 g/1g
Aerosol, meteredNasal
Powder, for solutionOral
PowderOral1 g/1g
Powder, for solutionOral1 g/1g
Powder, for solutionOral17 g/1
Powder, for solutionOral60 g/1L
Powder, for solutionOral17 g/1d
Powder, for solutionOral17 g/1g
Powder, for solutionOral17 g/17g
Powder, for solutionOral
Spray, meteredNasal
Powder, for solutionNasogastric; Oral
Not Available
Patent NumberPediatric ExtensionApprovedExpires (estimated)
Additional Data Available
  • Filed On
    Filed On

    The date on which a patent was filed with the relevant government.

    Learn more


Experimental Properties
melting point (°C)58-61MSDS
boiling point (°C)>200MSDS
Predicted Properties
Not Available
Predicted ADMET features
Not Available


Mass Spec (NIST)
Not Available
Not Available


Not classified


Pharmacological action
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
Uniprot ID
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
  1. Shen Q, Lin Y, Handa T, Doi M, Sugie M, Wakayama K, Okada N, Fujita T, Yamamoto A: Modulation of intestinal P-glycoprotein function by polyethylene glycols and their derivatives by in vitro transport and in situ absorption studies. Int J Pharm. 2006 Apr 26;313(1-2):49-56. doi: 10.1016/j.ijpharm.2006.01.020. Epub 2006 Feb 24. [PubMed:16500056]
  2. Wang SW, Monagle J, McNulty C, Putnam D, Chen H: Determination of P-glycoprotein inhibition by excipients and their combinations using an integrated high-throughput process. J Pharm Sci. 2004 Nov;93(11):2755-67. doi: 10.1002/jps.20183. [PubMed:15389668]
  3. Werle M: Natural and synthetic polymers as inhibitors of drug efflux pumps. Pharm Res. 2008 Mar;25(3):500-11. doi: 10.1007/s11095-007-9347-8. Epub 2007 Sep 26. [PubMed:17896100]

Drug created on October 29, 2015 12:17 / Updated on April 03, 2020 10:37

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.